immunotherapy

Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023

SEATTLE, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of…

1 year ago

PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer

PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage…

1 year ago

ADvantage Therapeutics Has Commenced Enrollment for Its Phase 2b Clinical Trial of AD04™ for Treatment of Alzheimer’s Disease

MIAMI, Nov. 27, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for…

1 year ago

Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference

SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a…

1 year ago

Alladapt Immunotherapeutics Receives FDA Fast Track Designation for ADP101 for the Treatment of Mono- and Multi-Food Allergies

– Fast Track Designation accelerates ADP101's development path for the treatment of mono- and multi-food allergy – – Phase 1/2…

1 year ago

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

SYDNEY, AUSTRALIA, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage…

1 year ago

Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical…

1 year ago

SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors

SIOUX FALLS, S.D., Nov. 20, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel…

1 year ago

IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

All patients treated with INB-200 who completed mandated doses to date have exceeded a progression-free survival (PFS) of seven months…

1 year ago